Interestingly, 37% of patients with AML who failed Gilteritinib therapy exhibited RAS/MAPK mutations as well as the emergence of additional new mutations (including BRAF, CBL, KRAS, PTPN11, RUNX1, WT1, and CEBPA), which were undetected prior to Gilteritinib treatment (2). This evidence concerns the gene BRAF and acute myeloid leukemia.